Semaglutide is a medication used for the treatment of type 2 diabetes and weight management. It primarily helps control blood sugar and body weight by mimicking a hormone in the body known as glucagon-like peptide-1 (GLP-1).

Semaglutide not only excels at lowering blood sugar but also offers potential benefits for cardiovascular health. Studies indicate that long-term use of the drug may reduce the incidence of cardiovascular events-such as heart disease and stroke-in patients with type 2 diabetes.

As a GLP-1 receptor agonist, semaglutide enhances insulin secretion and reduces glucose production, thereby effectively controlling postprandial (after-meal) blood sugar levels. This is particularly important for patients with type 2 diabetes, as the condition is typically associated with insulin resistance and insufficient insulin secretion.

Clinical studies have shown that patients treated with semaglutide experienced an average reduction of 1–1.5 percentage points in glycated hemoglobin (HbA1c), indicating a significant improvement in blood sugar control. Additionally, some studies demonstrate that semaglutide is highly effective for weight management, with users achieving weight loss of approximately 5–10%.